# Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

> **NCT03794349** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 94 (actual)

## Conditions studied

- High Risk Neuroblastoma
- Recurrent Neuroblastoma
- Refractory Neuroblastoma

## Interventions

- **BIOLOGICAL:** Dinutuximab
- **DRUG:** Eflornithine Hydrochloride
- **DRUG:** Irinotecan Hydrochloride
- **BIOLOGICAL:** Sargramostim
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03794349
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-08
- **Primary completion:** 2025-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794349, "Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03794349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*